Ophthalmology

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared advice for young scientists entering the cell and gene therapy field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the unpredictability of "living drugs" in the human body and the ongoing development of understanding.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on how streamlined collaboration can help move therapies to patients faster.

Review top news and interview highlights from the week ending October 24, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The IND application enabling the launch of the CELESTE trial in the US was previously cleared by the FDA in July 2025.

Review top news and interview highlights from the week ending October 17, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Krystal is the second company to have received the new FDA designation.

The RDEA program is meant to support use of novel end points for measuring efficacy in clinical studies for therapies aimed at treating rare diseases.

Review top news and interview highlights from the week ending October 10, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 3, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending September 26, 2025.

SAR446268 has previously received orphan drug designations from the FDA and European Medicines Agency.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Part B of LIGHTHOUSE enrolled 9 patients and is expected to enroll 3 pediatric patients.

Review top news and interview highlights from the week ending September 19, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SAR402663 comprises a onetime intravitreal treatment and is intended to inhibit VEGF by providing a gene for soluble FLT01.

Review top news and interview highlights from the week ending September 12, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending September 5, 2025.